Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PhytoMedical Technologies has reported positive results from new tests of the company's next generation anticancer compounds, which have demonstrated the ability to kill difficult-to-treat human cancer cells, including colon cancer cells and human glioblastoma cells related to brain cancer.
Subscribe to our email newsletter
In important tests against a difficult-to-treat strain of human colon cancer cells (HCT116), scientists evaluated the performance of concentrated amounts of company’s newest anticancer compounds. Researchers observed a 50% or greater cancer cell kill rate using these patented compounds, reporting excellent success in the company’s second Phase tests where they have employed new, synthetic bis-acridines for the first time.
Greg Wujek, president and CEO of PhytoMedical, said: “Based on encouraging outcomes from early Phase one research into our first-generation anticancer compounds, we immediately bolstered our efforts and initiated tests of our next-generation compounds. These Phase two tests were specifically designed to target difficult-to-treat strains of human cancer cells, and the resulting outcomes have been very favorable.”